Preclinical studies suggest that GLP-1 receptor activation in the mesolimbic dopamine system appears to modulate dopamine signaling, which is central to the rewarding effects of alcohol and other addictive substances
Even if it is just due to the benefits of weight loss, reducing the burden of AFib and other CV conditions with a single drug is hard to dismiss.
Anyone researching Akkermansia probiotics for metabolic wellness should understand this pathway first: Akkermansia does not replace GLP-1 activity, but it may help support the gut conditions that influence metabolic signaling, including mucosal integrity, SCFA production, inflammatory balance, and microbiome resilience
FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Compounding and the FDA: Questions and Answers Understanding unapproved versions of these drugs FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss
doi: 10.1016/S1262-3636(17)30067-8
Plant Powered, Clinically Proven GLP-1 Support for Sustainable Metabolic Health
